Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [1][3] - The company utilizes its RNA medicines platform, PRISM®, which integrates various modalities and innovations in chemistry to address both rare and prevalent disorders [3] Upcoming Event - Paul Bolno, MD, MBA, President and CEO of Wave Life Sciences, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET [1] Pipeline and Research Focus - Wave Life Sciences has a diversified pipeline that includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington’s disease, along with a preclinical program in obesity [3] - The company aims to leverage its RNA-targeting modalities, which include editing, splicing, RNA interference, and antisense silencing, to develop effective treatments [3]